TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock - PubMed (original) (raw)

. 1994 Oct;42(3-4):128-34.

doi: 10.1007/BF01983478.

Affiliations

• PMID: 7879698
• DOI: 10.1007/BF01983478

TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock

P Canale et al. Agents Actions. 1994 Oct.

Abstract

The aim of this study was to evaluate: (1) the accumulation of leukocytes in the ileum and the lung during splanchnic artery occlusion (SAO) shock; (2) the role of platelet-activating factor (PAF) and tumor necrosis factor (TNF-alpha) in this phenomenon. Untreated anesthesized rats subjected to total occlusion of the celiac, superior and inferior mesenteric arteries for 45 min, followed by reperfusion, uniformly died within 90 min after reperfusion. The mean survival time was 93 +/- 7 min. The neutrophilic infiltrate was quantitated in the ileum and in the lung using a myeloperoxidase (MPO) assay. MPO activity in the ileum and in the lung averaged 0.05 +/- 0.03 and 0.4 +/- 0.02 U x 10(-3)/g protein in animals killed before occlusion. MPO activity did not change in rats killed immediately before reperfusion and was significantly elevated (0.11 +/- 0.02 and 1.7 +/- 0.6 U x 10(-3)/g protein in the ileum and the lung, respectively) in those killed 80 min after the beginning of the reperfusion. The histological examination confirmed the accumulation of leukocytes in the mucosa of the ileum and the lung over the 80 min. SAO shocked rats exhibited leukopenia and increased serum levels of TNF-alpha. In order to evaluate the role of PAF and TNF-alpha in SAO shock, a powerful PAF receptor antagonist, TCV-309 (5 micrograms/kg i.v.), was injected 5 min after reperfusion. TCV-309 increased survival time, lowered serum TNF-alpha, reduced MPO activity in both the ileum and the lung and ameliorated leukopenia induced by SAO shock.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Similar articles

• Platelet activating factor interaction with tumor necrosis factor in myocardial ischaemia-reperfusion injury.
  Squadrito F, Ioculano M, Altavilla D, Zingarelli B, Canale P, Campo GM, Saitta A, Calapai G, Bussolino F, Caputi AP. Squadrito F, et al. J Lipid Mediat. 1993 Aug;8(1):53-65. J Lipid Mediat. 1993. PMID: 8257777
• Tumor necrosis factor induces E-selectin production in splanchnic artery occlusion shock.
  Altavilla D, Squadrito F, Canale P, Ioculano M, Campo GM, Squadrito G, Saitta A, Caputi AP. Altavilla D, et al. Am J Physiol. 1995 Apr;268(4 Pt 2):H1412-7. doi: 10.1152/ajpheart.1995.268.4.H1412. Am J Physiol. 1995. PMID: 7537468
• The effects of recombinant human granulocyte-colony stimulating factor on vascular dysfunction and splanchnic ischaemia-reperfusion injury.
  Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Ammedolia L, Arlotta M, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1997 Jan;120(2):333-9. doi: 10.1038/sj.bjp.0700904. Br J Pharmacol. 1997. PMID: 9117128 Free PMC article.
• Platelet activating factor involvement in splanchnic artery occlusion shock in rats.
  Squadrito F, Sturniolo R, Altavilla D, Santoro G, Campo GM, Arena A, Caputi AP. Squadrito F, et al. Eur J Pharmacol. 1991 Jan 3;192(1):47-53. doi: 10.1016/0014-2999(91)90067-z. Eur J Pharmacol. 1991. PMID: 2040364
• Platelet activating factor interaction with tumor necrosis factor and myocardial depressant factor in splanchnic artery occlusion shock.
  Zingarelli B, Squadrito F, Ioculano M, Altavilla D, Bussolino F, Campo GM, Caputi AP. Zingarelli B, et al. Eur J Pharmacol. 1992 Nov 3;222(1):13-9. doi: 10.1016/0014-2999(92)90456-e. Eur J Pharmacol. 1992. PMID: 1468489

Cited by

• Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.
  Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Canale P, Rossi F, Saitta A, Caputi AP. Squadrito F, et al. Br J Pharmacol. 1996 Sep;119(1):23-8. doi: 10.1111/j.1476-5381.1996.tb15672.x. Br J Pharmacol. 1996. PMID: 8872352 Free PMC article.
• Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia of the superior mesenteric artery in the rat.
  Souza DG, Cara DC, Cassali GD, Coutinho SF, Silveira MR, Andrade SP, Poole SP, Teixeira MM. Souza DG, et al. Br J Pharmacol. 2000 Dec;131(8):1800-8. doi: 10.1038/sj.bjp.0703756. Br J Pharmacol. 2000. PMID: 11139461 Free PMC article.
• Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment.
  Souza DG, Pinho V, Soares AC, Shimizu T, Ishii S, Teixeira MM. Souza DG, et al. Br J Pharmacol. 2003 Jun;139(4):733-40. doi: 10.1038/sj.bjp.0705296. Br J Pharmacol. 2003. PMID: 12812996 Free PMC article.

References

1. 1. J Pharmacol Exp Ther. 1990 Oct;255(1):256-63 - PubMed
2. 1. J Pharmacol Methods. 1985 Nov;14(3):157-67 - PubMed
3. 1. J Exp Med. 1987 Nov 1;166(5):1390-404 - PubMed
4. 1. Pharmacol Rev. 1987 Jun;39(2):97-145 - PubMed
5. 1. J Immunol. 1980 Oct;125(4):1671-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal